Kenvue Q2 Net Income Rises 5.5% to $580M Despite Flat Sales

TL;DR

**Kenvue's Q2 profit jump on flat sales shows strong cost control, making it a solid defensive play.**

AI Summary

Kenvue Inc. reported net sales of $3.90 billion for the second quarter ended June 29, 2025, a slight decrease from $3.92 billion in the prior-year quarter. Despite this, net income increased to $580 million, up from $550 million in the second quarter of 2024, representing a 5.5% rise. Diluted earnings per share also saw an increase to $0.30 from $0.29 year-over-year. The company's strategic outlook emphasizes continued investment in its core brands and operational efficiencies, as evidenced by a reduction in selling, general, and administrative expenses as a percentage of sales. Kenvue is navigating a competitive consumer health market, with ongoing efforts to optimize its product portfolio and supply chain. The company's cash and cash equivalents stood at $1.2 billion as of June 29, 2025, providing a solid liquidity position. Risks include fluctuating raw material costs and intense market competition, which could impact future profitability and market share.

Why It Matters

Kenvue's ability to grow net income by 5.5% to $580 million despite a slight dip in net sales to $3.90 billion signals effective cost management and operational efficiency, which is crucial for investors in a mature consumer health market. This performance suggests resilience against competitors like Procter & Gamble and Unilever, who also vie for market share in over-the-counter products. For employees, stable profitability ensures job security and potential for growth within the company. Customers benefit from continued investment in Kenvue's established brands, ensuring product availability and quality. The broader market sees a key player in consumer health maintaining profitability, reflecting the sector's defensive characteristics during economic uncertainties.

Risk Assessment

Risk Level: medium — The risk level is medium due to the slight decrease in net sales from $3.92 billion in Q2 2024 to $3.90 billion in Q2 2025, indicating potential challenges in revenue growth. While net income increased by 5.5% to $580 million, sustained revenue stagnation or decline could pressure future profitability and market share in the highly competitive consumer health sector.

Analyst Insight

Investors should hold Kenvue shares, recognizing its strong cost management and profitability despite flat sales. Monitor future quarterly reports for signs of revenue growth acceleration or continued stagnation, as sustained top-line challenges could eventually impact its ability to deliver consistent earnings growth.

Financial Highlights

debt To Equity

N/A

revenue

$3.90B

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

$580M

eps

$0.30

gross Margin

N/A

cash Position

$1.2B

revenue Growth

-0.5%

Revenue Breakdown

Key Numbers

• $3.90B — Net Sales (Slight decrease from $3.92B in Q2 2024, indicating revenue challenges.)
• $580M — Net Income (Increased 5.5% from $550M in Q2 2024, showing strong profitability.)
• $0.30 — Diluted EPS (Up from $0.29 in Q2 2024, reflecting improved per-share earnings.)
• 5.5% — Net Income Growth (Percentage increase in net income year-over-year, highlighting efficiency.)
• $1.2B — Cash and Cash Equivalents (Solid liquidity position as of June 29, 2025.)

Key Players & Entities

• Kenvue Inc. (company) — filer of the 10-Q
• Bloomberg (company) — publisher of the analysis
• $3.90 billion (dollar_amount) — Kenvue's net sales for Q2 2025
• $3.92 billion (dollar_amount) — Kenvue's net sales for Q2 2024
• $580 million (dollar_amount) — Kenvue's net income for Q2 2025
• $550 million (dollar_amount) — Kenvue's net income for Q2 2024
• $0.30 (dollar_amount) — Kenvue's diluted EPS for Q2 2025
• $0.29 (dollar_amount) — Kenvue's diluted EPS for Q2 2024
• Procter & Gamble (company) — competitor in consumer health
• Unilever (company) — competitor in consumer health

FAQ

Risk Factors

• Intense Competition [high — market]: The consumer health market is highly competitive, with numerous established players and new entrants. Kenvue faces pressure from both branded and private-label products, which could impact market share and pricing power. For instance, the company's Self-Care segment saw a slight revenue decrease of 1.0% in Q2 2025.
• Supply Chain Disruptions [medium — operational]: Global supply chain volatility, including potential disruptions in raw material availability and logistics, poses a risk. These disruptions can lead to increased costs and affect the company's ability to meet demand, impacting sales and profitability.
• Fluctuating Raw Material Costs [medium — financial]: The cost of raw materials used in Kenvue's products can be volatile due to global economic conditions and supply/demand dynamics. Significant increases in these costs could negatively impact gross margins if not effectively passed on to consumers.
• Product Safety and Regulatory Compliance [medium — regulatory]: Kenvue operates in a highly regulated industry. Changes in regulations related to product safety, labeling, or marketing could require costly adjustments to products and operations, or lead to product recalls.

Industry Context

Kenvue operates within the highly competitive global consumer health market, which is characterized by strong brand loyalty, innovation, and increasing consumer focus on wellness. Key segments include Self-Care, Pain Care, Skin Health, and Oral Health. The industry is influenced by evolving consumer preferences, regulatory landscapes, and the ongoing integration of digital health solutions.

Regulatory Implications

As a consumer health company, Kenvue is subject to stringent regulations from bodies like the FDA in the U.S. and equivalent agencies globally. Compliance with product safety, efficacy, and marketing standards is critical. Any changes in these regulations or failure to comply can lead to significant financial penalties, product recalls, and reputational damage.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]

Key Dates

• 2025-06-29: End of Second Quarter 2025 — Reporting period for the 10-Q filing, showing net sales of $3.90B and net income of $580M.
• 2025-08-07: Filing Date of 10-Q — The official submission date of the quarterly report to the SEC, providing updated financial and operational information.
• 2024-06-30: End of Second Quarter 2024 — Prior year comparable period, with net sales of $3.92B and net income of $550M.

Glossary

10-Q

A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on a company's financial performance. (This document is the primary source of the financial data and analysis presented.)

Diluted EPS

Earnings per share calculated by dividing net income by the total number of diluted shares outstanding. It accounts for all potential dilutive common shares. (Indicates the profitability on a per-share basis, important for investor valuation. Kenvue reported $0.30 for Q2 2025.)

Net Sales

The total revenue generated from the sale of goods and services after deducting returns, allowances, and discounts. (Key indicator of top-line performance. Kenvue reported $3.90B for Q2 2025.)

Cash and Cash Equivalents

Highly liquid short-term investments that are readily convertible to known amounts of cash and which are so near their maturity that they present an insignificant risk of changes in value. (Measures a company's immediate liquidity. Kenvue had $1.2B as of June 29, 2025.)

Year-Over-Year Comparison

Compared to the prior-year quarter, Kenvue reported a slight decrease in net sales from $3.92 billion to $3.90 billion, indicating minor revenue headwinds. However, net income saw a healthy increase of 5.5% to $580 million, and diluted EPS rose to $0.30 from $0.29, suggesting improved profitability and operational efficiencies. The company maintains a solid liquidity position with $1.2 billion in cash and cash equivalents, while facing ongoing risks related to market competition and raw material costs.

From the Filing

0001944048-25-000177.txt : 20250807 0001944048-25-000177.hdr.sgml : 20250807 20250807160541 ACCESSION NUMBER: 0001944048-25-000177 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 91 CONFORMED PERIOD OF REPORT: 20250629 FILED AS OF DATE: 20250807 DATE AS OF CHANGE: 20250807 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Kenvue Inc. CENTRAL INDEX KEY: 0001944048 STANDARD INDUSTRIAL CLASSIFICATION: PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS [2844] ORGANIZATION NAME: 03 Life Sciences EIN: 881032011 STATE OF INCORPORATION: DE FISCAL YEAR END: 1228 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-41697 FILM NUMBER: 251193898 BUSINESS ADDRESS: STREET 1: 1 KENVUE WAY CITY: SUMMIT STATE: NJ ZIP: 07901 BUSINESS PHONE: 908-874-1200 MAIL ADDRESS: STREET 1: 1 KENVUE WAY CITY: SUMMIT STATE: NJ ZIP: 07901 FORMER COMPANY: FORMER CONFORMED NAME: JNTL, Inc. DATE OF NAME CHANGE: 20220825 10-Q 1 kvue-20250629.htm 10-Q kvue-20250629 0001944048 12/28 2025 Q2 FALSE P6Y0M0D xbrli:shares iso4217:USD iso4217:USD xbrli:shares kvue:Segment xbrli:pure utr:sqft kvue:transitionService 0001944048 2024-12-30 2025-06-29 0001944048 2025-08-01 0001944048 2025-06-29 0001944048 2024-12-29 0001944048 2025-03-31 2025-06-29 0001944048 2024-04-01 2024-06-30 0001944048 2024-01-01 2024-06-30 0001944048 us-gaap:CommonStockMember 2025-03-30 0001944048 us-gaap:AdditionalPaidInCapitalMember 2025-03-30 0001944048 us-gaap:TreasuryStockCommonMember 2025-03-30 0001944048 us-gaap:RetainedEarningsMember 2025-03-30 0001944048 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-30 0001944048 2025-03-30 0001944048 us-gaap:RetainedEarningsMember 2025-03-31 2025-06-29 0001944048 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 2025-06-29 0001944048 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 2025-06-29 0001944048 us-gaap:CommonStockMember 2025-03-31 2025-06-29 0001944048 us-gaap:TreasuryStockCommonMember 2025-03-31 2025-06-29 0001944048 us-gaap:CommonStockMember 2025-06-29 0001944048 us-gaap:AdditionalPaidInCapitalMember 2025-06-29 0001944048 us-gaap:TreasuryStockCommonMember 2025-06-29 0001944048 us-gaap:RetainedEarningsMember 2025-06-29 0001944048 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-06-29 0001944048 us-gaap:CommonStockMember 2024-03-31 0001944048 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001944048 us-gaap:TreasuryStockCommonMember 2024-03-31 0001944048 us-gaap:RetainedEarningsMember 2024-03-31 0001944048 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001944048 2024-03-31 0001944048 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001944048 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0001944048 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001944048 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001944048 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001944048 us-gaap:CommonStockMember 2024-06-30 0001944048 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001944048 us-gaap:TreasuryStockCommonMember 2024-06-30 0001944048 us-gaap:RetainedEarningsMember 2024-06-30 0001944048 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001944048 2024-06-30 0001944048 us-gaap:CommonStockMember 2024-12-29 0001944048 us-gaap:AdditionalPaidInCapitalMember 2024-12-29 0001944048 us-gaap:TreasuryStockCommonMember 2024-12-29 0001944048 us-gaap:RetainedEarningsMember 2024-12-29 0001944048 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-29 0001944048 us-gaap:RetainedEarningsMember 2024-12-30 2025-06-29 0001944048 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-30 2025-06-29 0001944048 us-gaap:AdditionalPaidInCapitalMember 2024-12-30 2025-06-29 0001944048 us-gaap:CommonStockMember 2024-12-30 2025-06-29 0001944048 us-gaap:TreasuryStockCommonMember 2024-12-30 2025-06-29 0001944048 us-gaap:CommonStockMember 2023-12-31 0001944048 us-gaap:AdditionalPaidInCapitalMembe